Most of the pathogenic DMD variants can be identified by DNA-based standard genetic testing for dystrophinopathies, consisting of multiplex ligation-dependent probe amplification (MLPA) and short-read sequencing of 79 exons and adjacent intronic regions of DMD (Fratter et al., 2020; Neri et al., 2020; Xie et al., 2021). The gene discussed is DMD; the disease is neuromuscular disease caused by qualitative or quantitative defects of dystrophin.